RU99105211A

RU99105211A - ARILALKANOILPYRIDAZINES

Info

Publication number: RU99105211A
Application number: RU99105211/04A
Authority: RU
Inventors: Йонас Рохус; Норберт Байер; Франц-Вернер КЛУКСЕН; Михель ВОЛЬФ
Original assignee: Мерк Патент Гмбх
Priority date: 1996-08-13
Filing date: 1997-08-01
Publication date: 2001-01-20

Claims

1. The compounds of formula I

where B is A, OA, NH ₂ , NHA, NAA 'or an aromatic heterocycle with 1 to 4 N, O and / or S atoms, which is unsubstituted or may be substituted one, two or three times Hal, A and / or OA,
Q is absent or denotes alkylene with 1-6 carbon atoms,
R ¹ , R ² independently of one another denote -OH, OR ⁵ , -SR ⁵ , -SO-R ⁵ , -SO ₂ -R ⁵ , Hal, -NO ₂ , -NH ₂ , -NHR ⁵ or -NR ⁵ R ⁶
R ¹ and R ² together also denote-O-CH ₂ -O-,
R ⁵ , R ⁶ independently of one another denote A, cycloalkyl with 3-7 carbon atoms, methylenecycloalkyl with 4-8 carbon atoms or alkenyl with 2-8 carbon atoms,
A, A 'independently of one another denote alkyl with 1-10 carbon atoms, which may be substituted with 1-5 F and / or Cl atoms, and
Hal means F, Cl, Br or I,
and their physiologically acceptable salts.

2. The compounds of formula 1 under item 1, representing
(a) 1- (4-nicotinoylamino-benzoyl) -3- (3-ethoxy-4-methoxyphenyl) -1,4,5,6-tetrahydropyridazine,
(b) 1- (4-ethoxycarbonylamino-benzoyl) -3- (3-ethoxy-4-methoxyphenyl) -1,4,5,6-tetrahydropyridazine,
(c) 1- (4-nicotinoylamino-benzoyl) -3- (3-cyclopentyloxy-4-methoxyphenyl) -1,4,5,6-tetrahydropyridazine,
(d) 1- (4-ethoxycarbonylamino-benzoyl) -3- (3-cyclopentyloxy-4-methoxyphenyl) -1,4,5,6-tetrahydropyridazine,
(e) 1- (4-isonicicotinylamino-benzoyl) -3- (3-ethoxy-4-methoxy-phenyl) -1,4,5,6-tetrahydropyridazine,
(e) 1- (4-isonicicotinylamino-benzoyl) -3- (3-cyclopentyloxy-4-methoxyphenyl) -1,4,5,6-tetrahydropyridazine,
(g) 1- (4-nicotinoylamino-benzoyl) -3- (3,4-dimethoxyphenyl) -1,4,5,6-tetrahydropyridazine,
(h) 1- (4-ethoxycarbonylamino-benzoyl) -3- (3,4-dimethoxyphenyl) -1,4,5,6-tetrahydropyridazine.

3. The method of producing compounds of formula I according to claim 1, as well as their salts, characterized in that the compound of formula II

where R ¹ and R ² have the above values,
subjected to interaction with the compound of the formula III

where B and Q have the above meanings and L denotes Cl, Br, OH or reactive esterified OH group,
or a compound of formula IV

where R ¹ , R ² and Q have the above values,
subjected to interaction with the compound of the formula V
B-CO-L
where B has the indicated meaning and L denotes Cl, Br, OH, or a reactive OH-esterified group,
and / or the basic compound of the formula I is converted into one of its salts by treatment with an acid.

4. A method for preparing pharmaceutical compositions, characterized in that a compound of the formula I according to claim 1 and / or one of its physiological acceptable salts, together with at least one solid, liquid or semi-liquid carrier or auxiliary substance, is transferred to a suitable dosage form.

5. A pharmaceutical composition characterized by the content of at least one compound of the formula I according to claim 1 and / or one of its physiologically acceptable salts.

6. The compounds of formula I according to claim 1 and their physiologically acceptable salts for the treatment of asthma, allergies and inflammatory diseases, autoimmune diseases and graft rejection reactions.

7. Drug of the formula I according to claim 1 and their physiologically acceptable salts as phosphodiesterase IV inhibitors.

8. The compounds of formula I according to claim 1 and / or their physiologically acceptable salts for the preparation of a medicament.

9. The compounds of formula I under item 1 and / or their physiologically acceptable salts for the treatment of diseases.